Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Polypeptide capable of treating Alzheimer's disease and vaccine containing polypeptide capable of treating Alzheimer's disease

A technology for Alzheimer's disease and polypeptide vaccine, applied in the field of protein engineering, can solve problems such as insecurity, and achieve the effects of prolonging survival, preventing the formation and accumulation of β-amyloid, and having extensive clinical application value.

Inactive Publication Date: 2019-06-07
横琴欣健生物科技研究院有限公司
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, after testing, it was found to be unsafe and had great side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polypeptide capable of treating Alzheimer's disease and vaccine containing polypeptide capable of treating Alzheimer's disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Example 1: Polypeptide Synthesis by Solid Phase Polypeptide Synthesis

[0026] All the reagents used below were purchased from Jill Biochemical (Shanghai) Co., Ltd.;

[0027] 1. Take 1.5g of dichloro resin, add it to the reaction column soaked in DCM, soak in 15ml of DCM for 30min to fully expand the resin, and activate it for use;

[0028] 2. Weigh 0.31g of Fmoc-Cys(Acm).OH and dissolve it in DCM, then add 0.5ml of DIEA and mix it into the reaction vessel, blow N 2 After reacting for 2 hours, filter the reaction solution, add 5ml of MeOH to block the reaction for 1 hour, and then wash with DCM, isopropanol and DMF for 3 times;

[0029] 3. Remove the amino protecting group: add about 15ml of 20% piperidine in DMF solution for 5 minutes, filter, then add 15ml and react for 20 minutes, wash the resin twice with isopropanol, and wash the resin 3 times with DMF;

[0030] 4. Formation of peptide bonds: Weigh 0.55g Fmoc-Trp(600)-OH, dissolve 0.35g TBTU in DMF, mix with 0.6m...

Embodiment 2

[0032] Example 2: Polypeptide Synthesis by Solid-Phase Polypeptide Synthesis

[0033] The peptide synthesizer adopts the American AB1431A model, and the peptide solid-phase synthesis, resin selection and activation treatment are purchased from Jill Biochemical (Shanghai) Co., Ltd.

[0034] Peptide synthesis is actually a process of repeated addition of amino acids, and the synthesis is generally synthesized from the carboxyl terminal (C-terminal) to the amino-terminal (N-terminal). The basic principle of solid-phase synthesis of peptides is: use insoluble polymer resin as a solid-phase carrier, first link an amino acid containing an amino group protected by a blocking group on the solid-phase carrier with a covalent bond, and then use trifluoroacetic acid as a deprotection agent. Reagent, remove the protecting group of the amino group, so that the first amino acid is connected on the solid support. Activate the carboxyl group of the second amino acid with a protective group b...

Embodiment 3

[0045] Embodiment three: adopt genetic recombination synthetic polypeptide

[0046] Use genetic engineering technology to use probiotics and yeast to secrete and produce the polypeptide drug of the present invention, and use methods such as yogurt, solid drinks, beer, etc. to use probiotics and yeast to grow and reproduce in the intestinal tract to continuously secrete and produce various diseases. Preventive and therapeutic Peptide drugs. Apply genetic engineering technology to construct probiotics and yeast polypeptide drug and vaccine vectors, and clone antigen genes and cytokine genes to probiotics and yeast plasmids. After the transformation of probiotics and yeast, the peptide drug products containing the expression of the target gene are screened out and used as seed peptide drugs for cryopreservation, and the seed peptide drugs are scaled up for cultivation.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a polypeptide capable of treating Alzheimer's disease and a vaccine containing the polypeptide capable of treating the Alzheimer's disease. The polypeptide drug has an amino acid sequence selected from any one selected from the amino acid sequences shown in SEQ ID NO. 1 to SEQ ID No. 10. The polypeptide drug is capable of prolonging survival periods of mice with the Alzheimer's disease; and thus, the polypeptide drug disclosed by the invention can be used as a drug candidate for treating the Alzheimer's disease. Thus, the polypeptide drug has extensive clinical application values.

Description

technical field [0001] The invention relates to the technical field of protein engineering, in particular to a polypeptide for treating senile dementia and a vaccine thereof. Background technique [0002] Alzheimer's disease or senile Alzheimer's disease (Alzheimer's disease, AD) is a common disease of the elderly worldwide, accounting for the fourth cause of human death. It was discovered by Bavarian neuropathologist Alzheimer in 1907. It was first discovered and named after it. AD is a diffuse central neurodegenerative disease characterized by progressive cognitive impairment, mental decline, and personality changes, with brain amyloid Aβ1-42 deposition, neurofibrillary tangles, neuronal loss, and slow inflammation Sexual pathological features. The etiology and pathogenesis of AD are still not very clear, but clinically it can be manifested as progressive memory impairment, cognitive dysfunction and behavioral changes. In particular, AD lacks objective and effective ind...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/06C07K14/00A61K39/00A61K39/385A61K39/39A61P25/28
Inventor 叶学敏罗祖樑叶学维周嘉刘兰英
Owner 横琴欣健生物科技研究院有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com